Page 16 - For Media News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from For media. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In For Media Today - Breaking & Trending Today

AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to develop and commercialise NI006

Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition ....

United States , United Kingdom , Geriatr Cardiol , Marc Dunoyer , Investor Relations Team , Company On Twitter , Alexion Pharmaceuticals Inc , Rare Disease , Chief Executive Officer , Astrazeneca Rare Disease , Alexion Pharmaceuticals , Rare Diseases , For Media , Open Heart , Neurol Ther , Intj Cardiol , Patients Have Worse Outcomes , Heart Failure , Primary Care Based Cohort Study , Eurj Heart Fail , Chronic Heart Failure , Breast Cancer , Merger And Acquisition , Amyloid Cardiomyopathy , Branches Of Biology , Cardiac Amyloidosis ,

AstraZeneca and Ionis close agreement to develop and commercialise eplontersen

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. ....

United Kingdom , United States , Company On Twitter , Investor Relations Team , Ionis Pharmaceuticals Inc , Ionis Pharmaceuticals , Rare Diseases , For Media , Branches Of Biology , Cardiac Amyloidosis , Familial Amyloid Neuropathy , Familial Amyloid Polyneuropathy , Morgan Systems ,

Ultomiris regulatory submission accepted under FDA Priority Review in the US for adults with generalised myasthenia gravis

Submission based on positive Phase III trial in which Ultomiris significantly improved functional activities as measured by Myasthenia Gravis-Activities of Daily Living Profile ....

United States , Kuldigas Novads , United Kingdom , Republic Of Ireland , Marc Dunoyer , National Organization For Rare Disorders , Company On Twitter , Drug Administration , Alexion Pharmaceuticals Inc , Investor Relations Team , European Union , National Institutes Of Neurological Disorders , York Academy Of Sciences , Myasthenia Gravis Activities , Daily Living , Biologics License Application , Priority Review , Prescription Drug User Fee Act , Rare Disease , Chief Executive Officer , North America , Daily Living Profile , Myasthenia Gravis Foundation , America Clinical Classification Class , Astrazeneca Rare Disease , Alexion Pharmaceuticals ,

University of Louisville Health Adopts Paige AI-enabled Cancer Detection Software for Enhanced Cancer Detection

Press release content from Business Wire. The AP news staff was not involved in its creation. ....

University Of Louisville , United States , United Kingdom , Andy Moye , Jon Yu , Dibson Dibe Gondim , Thomas Fuchs , Paige Fullfocus , David Klimstra , Uofl Health , University Of Louisville School Medicine , University Of Louisville Uofl Health , Paige Software Development Kit , University Of Louisville Health , Residency Program , Laboratory Medicine , Memorial Sloan Kettering Cancer Center , Paige Prostate , Paige Breast , Pathology Informatics , Assistant Professor , Associate Residency Program Director , Anatomic Pathology , Genitourinary Pathology , Louisville School , Paige Platform ,

Lynparza granted Priority Review in the US for BRCA-mutated HER2-negative high-risk early breast cancer

AstraZeneca’s supplemental New Drug Application (sNDA) for Lynparza (olaparib) has been accepted and granted Priority Review in the US for the adjuvant treatment of patients with BRCA-mutated (BRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. ....

United States , United Kingdom , Daiichi Sankyo , Company On Twitter , Drug Administration , Frontier Science Technology Research Foundation , Breast International Group , American Society Of Clinical Oncology Annual Meeting , Merck Co Inc , Investor Relations Team , New Drug Application , Priority Review , Prescription Drug User Fee Act , Olympia Phase , Clinical Oncology Annual Meeting , New England Journal , Frontier Science , Technology Research Foundation , Rare Diseases , For Media , Accessed November , Scientific Reports , Combined With Endocrine Therapy , Adjuvant Treatment , Early Breast Cancer , Breast Cancer ,